By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Endo Pharmaceuticals Inc. v. Watson Laboratories Inc. et al.
1:11-cv-00575; filed June 29, 2011 in the District Court of Delaware
• Plaintiff: Endo Pharmaceuticals Inc.
• Defendants: Watson Laboratories Inc.; Watson Pharmaceuticals Inc.; Watson Pharma Inc.
Infringement of U.S. Patent Nos. 5,741,510 ("Adhesive Patch for Applying Analgesic Medication to the Skin," issued April 21, 1998), 6,096,333 ("Method of Forming Adhesive Patch for Applying Medication to the Skin," issued August 1, 2000), and 6,096,334 ("Adhesive Patch for Applying Medication to the Skin and Method," issued August 1, 2000), all licensed to Endo, following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Endo's Lidoderm® (lidocaine patch, used to treat after-shingles pain). View the complaint here.
ViiV Healthcare UK Ltd. et al. v. Lupin Ltd. et al.
1:11-cv-00576; filed June 29, 2011 in the District Court of Delaware
• Plaintiffs: ViiV Healthcare UK Ltd.; ViiV Healthcare Co.
• Defendants: Lupin Ltd.; Lupin Pharmaceuticals Inc.
Infringement of U.S. Patent No. 6,417,191 ("Synergistic Combination of Zidovudine, 1592U89 and 3TC," issued July 9, 2002) following a Paragraph IV certification as part of Lupin's filing of an ANDA to manufacture a generic version of ViiV's Trizivir® (abacavir sulfate, lamivudine, and zidovudine, used to treat HIV infection in humans). View the complaint here.
Somaxon Pharmaceuticals Inc. v. Mylan Inc. et al.
1:11-cv-00571; filed June 28, 2011 in the District Court of Delaware
• Plaintiff: Somaxon Pharmaceuticals Inc.
• Defendants: Mylan Inc.; Mylan Pharmaceuticals Inc.
Infringement of U.S. Patent No. 7,915,307 ("Methods of Improving the Pharmacokinetics of Doxepin," issued March 29, 2011) following Mylan's filing of an ANDA to manufacture a generic version of Somaxon's Silenor® (doxepin, used to treat insomnia). View the complaint here.
Hoffman-La Roche Inc. v. Accord Healthcare Inc. et al.
2:11-cv-03663; filed June 27, 2011 in the District Court of New Jersey
• Plaintiff: Hoffman-La Roche Inc.
• Defendants: Accord Healthcare Inc.; Intas Pharmaceutical Ltd.
Hoffmann-La Roche Inc. v. Teva Pharmaceuticals USA, Inc. et al.
2:11-cv-03635; filed June 23, 2011 in the District Court of New Jersey
• Plaintiff: Hoffmann-La Roche Inc.
• Defendants: Teva Pharmaceuticals USA, Inc.; Teva Pharmaceuticals Industries Ltd.
Hoffmann-La Roche Inc. v. Roxane Laboratories, Inc.
2:11-cv-03637; filed June 23, 2011 in the District Court of New Jersey
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 5,472,949 ("N4-(Substituted-Oxycarbonyl)-5'-Deoxy-5-Fluorocytidine Compounds, Compositions and Methods of Using Same," issued December 5, 1995) following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Roche's Xeloda® (capecitabine, used to treat breast and colorectal cancer and Dukes' C Stage III colon cancer). View the Teva complaint here.
Pfizer Inc. et al. v. Aurobindo Pharma Ltd. et al.
1:11-cv-00569; filed June 27, 2011 in the District Court of Delaware
• Plaintiffs: Pfizer Inc.; Pfizer Ireland Pharmaceuticals; Warner-Lambert Co.; Warner-Lambert Co. LLC
• Defendants: Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc.
Infringement of U.S. Patent No. 5,969,156 ("Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)," issued October 19, 1999) following a Paragraph IV certification as part of Aurobindo's filing of an ANDA to manufacture a generic version of Pfizer's Lipitor® (atorvastatin calcium, used to treat high cholesterol and heart disease). View the complaint here.
AstraZeneca LP et al. v. Watson Laboratories, Inc.
1:11-cv-03626; filed June 23, 2011 in the District Court of New Jersey
• Plaintiffs: AstraZeneca LP; AstraZeneca AB
• Defendant: Watson Laboratories, Inc.
Infringement of U.S. Patent Nos. 6,598,603 ("Method for Treating Respiratory Diseases," issued July 29, 2003) and 7,524,834 ("Sterile Powders, Formulations, and Methods for Producing the Same," issued April 28, 2009) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Astrazeneca's Pulmicort Respules® (budesonide inhalation suspension, used to treat asthma). View the complaint here.
Comments